FDA Names PLN-74809, Potential IPF Treatment, Orphan Drug to Speed Its Development
Pliant Therapeutics announced that its lead therapy candidate PLN-74809 was designated an orphan drug by the U.S. Food and Drug Administration (FDA), an act that helps to advance its development as a possible treatment of…